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In this review we focus on the role of orexin in cardio-respiratory functions and its potential
link to hypertension. (1) Orexin, cardiovascular function, and hypertension. In normal rats,
central administration of orexin can induce significant increases in arterial blood pressure
(ABP) and sympathetic nerve activity (SNA), which can be blocked by orexin receptor
antagonists. In spontaneously hypertensive rats (SHRs), antagonizing orexin receptors can
significantly lower blood pressure under anesthetized or conscious conditions. (2) Orexin,
respiratory function, and central chemoreception. The prepro-orexin knockout mouse
has a significantly attenuated ventilatory CO2 chemoreflex, and in normal rats, central
application of orexin stimulates breathing while blocking orexin receptors decreases
the ventilatory CO2 chemoreflex. Interestingly, SHRs have a significantly increased
ventilatory CO2 chemoreflex relative to normotensive WKY rats and blocking both orexin
receptors can normalize this exaggerated response. (3) Orexin, central chemoreception,
and hypertension. SHRs have higher ABP and SNA along with an enhanced ventilatory
CO2 chemoreflex. Treating SHRs by blocking both orexin receptors with oral administration
of an antagonist, almorexant (Almxt), can normalize the CO2 chemoreflex and significantly
lower ABP and SNA. We interpret these results to suggest that the orexin system
participates in the pathogenesis and maintenance of high blood pressure in SHRs, and
the central chemoreflex may be a causal link to the increased SNA and ABP in SHRs.
Modulation of the orexin system could be a potential target in treating some forms of
hypertension.
Keywords: orexin and orexin receptors, cardiorespiratory function, hypertension, CO2 chemoreflex, blood pressure
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INTRODUCTION
Orexins, also known as hypocretins (Hcrt), are two excita-
tory neuropeptides, orexin A and orexin B (OX-A and OX-B)
or hypocretin 1 and hypocretin 2 (Hcrt1 and Hcrt 2), pro-
duced by neurons primarily located in the lateral hypothalamic
area (LHA) (De Lecea et al., 1998; Sakurai et al., 1998). Both
OX-A and OX-B are derived from the same neuropeptide pre-
cursor, prepro-orexin (pp-OX or Hcrt gene). The actions of
OX-A and OX-B are mediated by two G-protein coupled recep-
tors, orexin receptor-1 (OX1R/HcrtR1) and orexin receptor-2
(OX2R/HcrtR2). Mounting evidence suggests that orexin is not
only important to sleep-wake cycle and feeding regulation but
also to respiratory and cardiovascular regulation. Furthermore,
orexin may play role in some types of hypertension.
OREXIN AND OREXIN RECEPTORS
The anatomical and physiological properties of the orexin sys-
tem have been reviewed extensively by many recent publications
(Sakurai, 2007; Tsujino and Sakurai, 2009; De Lecea, 2012). In
this review we focus only on orexin functions of most relevance
to cardio-respiratory regulation.
OREXIN NEURONS
In the central nervous system (CNS), the cell bodies of orexin
neurons are strictly located in the perifornical area and lat-
eral and dorsal hypothalamic areas (Peyron et al., 1998; Date
et al., 1999; Nambu et al., 1999). Orexin neurons receive affer-
ents from GABA, serotonin and catecholamine neurons, and
interact in the LHA with neurons that produce melanin con-
centrating hormone (MCH) and with neurons that express the
leptin receptor (LepR) (Bayer et al., 2005; Leinninger and Myers,
2008; Schone et al., 2011, 2012; Burdakov et al., 2013; Karnani
et al., 2013). Serotonin (5-HT) hyperpolarizes orexin neurons
through 5-HT1A receptor mediated G-protein-coupled inward
rectifier potassium channels (GIRK) in hypothalamic slices pre-
pared from orexin neuron/enhanced green fluorescent protein
(EGFP) transgenic mice (Muraki et al., 2004). The majority
of orexin-immunoreactive (OX-ir) neurons in LHA are sur-
rounded by dense tyrosine hydroxylase-immunoreactive (TH-ir)
axons (Yamanaka et al., 2006), but results of studies on the
role of catecholamines in orexin neurons are inconsistent. Bayer
et al. showed that noradrenaline depolarized and excited orexin
neurons (Bayer et al., 2005), while Yamanaka et al. reported
that catecholamines directly and indirectly inhibited orexin neu-
rons via α2-adrenoceptor mediated activation of GIRK channels
(Yamanaka et al., 2006).
In the LHA, three major types of neurons OX, MCH, and
LepRb expressing neurons are tightly intermingled and have a
complex interactive relationship. An emerging hypothesis is that
OX-MCH-LepR micro-circuits may act to regulate both auto-
nomic function and energy balance (Leinninger and Myers, 2008;
Hall et al., 2010; Leinninger, 2011; Burdakov et al., 2013). OX
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neurons are most active during wakefulness (Hassani et al., 2009),
and activation of orexin receptors promotes wakefulness (De
Lecea, 2010, 2012; Sakurai et al., 2010), feeding, and energy
metabolism (Tsujino and Sakurai, 2009; Teske et al., 2010; Girault
et al., 2012; Nixon et al., 2012), excites breathing, and stimulates
sympathetic nerve activity (SNA) leading to an increase in blood
pressure (Matsumura et al., 2001; Shirasaka et al., 2002; Zhang
et al., 2005; Huang et al., 2010; Shahid et al., 2011, 2012; Nattie
and Li, 2012). In contrast, MCH neurons are most active during
sleep (Hassani et al., 2009), and MCH promotes sleep or physi-
cal inactivity (Nahon, 2006; Peyron et al., 2009; Konadhode et al.,
2013; Monti et al., 2013), and regulates the autonomic nervous
system. Central administration of MCH via chronic intracere-
broventricular infusion (Messina and Overton, 2007) or acute
injection into the nucleus of the solitary tract (NTS) (Brown et al.,
2007) induces bradycardia and decreases blood pressure. Using
a fluorescent-tag to identify LepRb positive neurons, Leinninger
and Myers (2008); Leinninger (2011) demonstrated that in the
LHA LepRb neurons do not co-express OX or MCH, but rather
are co-distributed among the OX neurons (Figure 1). Both LepRb
andOX neurons are surrounded by theMCH-containing neurons
in the LHA (Leinninger and Myers, 2008; Leinninger, 2011). In
addition, LHA LepRb neurons have direct synapses with OX neu-
rons suggesting an important modulatory relationship between
LepRb and OX neurons in LHA (Louis et al., 2010).
OREXIN PROJECTIONS AND OREXIN RECEPTORS
In contract to the very localized property of the OX neurons,
OX axons are widely distributed throughout the CNS, with the
exception of the cerebellum (Peyron et al., 1998; Date et al., 1999;
Nambu et al., 1999). Based on in situ hybridization both OX1R
and OX2R mRNAs are distributed extensively in the same regions
that contain dense OX innervation (Trivedi et al., 1998; Marcus
et al., 2001), e.g., the forebrain, the hypothalamus, the brainstem
and the spinal cord. Both OX receptors and efferent projections
are found inmany sites involved in cardiovascular, respiratory and
thermo regulation, e.g., the paraventricular nucleus (PVN), NTS,
retrotrapezoidnucleus (RTN), locus coeruleus (LC),Kölliker-Fuse
nucleus, rostral ventrolateral medulla (RVLM), medullary raphe,
lateral paragigantocellular nucleus, midbrain periaqueductal gray,
A5 noradrenergic cell group, parabrachial region, area postrema,
intermediolateral cell column of the spinal cord and sympathetic
pre-ganglionic neurons (Peyron et al., 1998; Trivedi et al., 1998;
Date et al., 1999; Nambu et al., 1999; Marcus et al., 2001).
In the brainstem, networks of OX-ir fibers and terminals are
expressed on the neurons of all major catecholamine cell groups
[adrenaline (Adr): C1, C2, and C3 and noradrenaline (NA):
locus coeruleus, A1, A2, A4, A5 and A7] (Puskas et al., 2010).
Intracerebroventricular (icv) injection of orexin induces c-fos
expressioninthelocusceruleus,arcuatenucleus,centralgray,raphe
nuclei, NTS, supraoptic nucleus (SON), and PVN in Wistar rats
(Date et al., 1999). Thewidespreadnature and specific connections
of the orexin system suggests that orexin may be involved not
only in the regulation of the sleep-wake cycle and appetite but
alsoautonomicfunctions,particularlycardiorespiratoryfunctions.
Orexinmayact to link theregulationofcardiorespiratory functions
to wakefulness and sleep.
SUMMARY OF OREXIN NEURONS AND RECEPTORS
Both orexin projections and orexin receptors are enriched in the
neuronal sites that are importantly involved in cardio-respiratory
regulation, and they are well positioned to participate in the
regulation of cardio-respiratory functions.
THE ROLE OF OREXIN IN CARDIOVASCULAR FUNCTION
OREXIN, BLOOD PRESSURE, AND SYMPATHETIC NERVOUS SYSTEM
The sympathetic nervous system (SNS) plays a crucial role in
the regulation of circulation and blood pressure (Guyenet, 2006;
Fisher and Paton, 2011; Zubcevic et al., 2011), andmany neuronal
groups in the lateral hypothaluamus and brainstem are critically
involved in such regulation. It is known, that in vivo, electri-
cal or chemical stimulation of the perifornical nucleus of the
hypothalamus increases blood pressure and heart rate (HR) and
activates neurons of the lateral paragigantocellular area (Sun and
Guyenet, 1986; Allen and Cechetto, 1992). Soon after orexin and
orexin receptors were discovered in 1998, many studies started to
examine if orexin in the LHA participation in the regulation of
cardiovascular and sympathetic functions (Samson et al., 1999;
FIGURE 1 | Distribution of orexin (OX), melanin concentrating hormone
(MCH) and leptin receptor (LepRb) -expressing neurons in the lateral
hypothalamus (LHA). OX, MCH and LepRb-expressing neurons are
intermingled in the LHA, but there is no co-expression. Red dots, MCH
neurons; blue dots, OX neurons; green dots, LepRb neurons. F, Fornix; VMH,
ventromedial hypothalamus; DMH, dorsomedial hypothalamus; MT,
mammillothalamic tract (figure adapted with permission from Leinninger,
2011).
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Shirasaka et al., 1999; Matsumura et al., 2001). In vitro, orexin in
a dose-dependent manner, depolarizes neurons that are involved
in the regulation of blood pressure and sympathetic nerve activ-
ity (SNA), e.g., neurons in the hypothalamic PVN and the RVLM
(Shirasaka et al., 2001; Follwell and Ferguson, 2002; Huang et al.,
2010), as well as spinal cord sympathetic preganglionic neurons
(Antunes et al., 2001). In the RVLM both OX-A and OX-B depo-
larize neurons in a dose dependentmanner, and at 100 nM, orexin
excited ∼42% of neurons in the area. Application of an OX2R
antagonist (TCS-OX2-29) significantly reduced the number of
neurons activated by OX-A, while co-application of OX1R and
OX2R antagonists completely eliminated orexin A-induced depo-
larization (Figure 2) (Huang et al., 2010). Furthermore, about
88% of adrenergic, 43% of noradrenergic, and 36–41% of rhyth-
mically firing RVLM neurons can be excited by orexin in the
RVLM (Huang et al., 2010).
Functional studies in vivo have demonstrated that orexin
participates in blood pressure regulation. Transgenic orexin
deficient animals, both prepro-orexin knockout (pp-OX KO)
mice (Figure 3) and rats with orexin neurons-genetically ablated
(orexin/ataxin-3), have lower resting blood pressure (Kayaba
et al., 2003; Schwimmer et al., 2010) relative to their wild type
controls. In both anesthetized and unanesthetized normotensive
animals, central administration of OX-A or OX-B activates sym-
pathetic activity and increases both arterial blood pressure (ABP)
and HR (Samson et al., 1999; Shirasaka et al., 1999, 2002; Chen
et al., 2000; Antunes et al., 2001;Matsumura et al., 2001;Machado
et al., 2002; Shahid et al., 2011, 2012). In conscious rats and
rabbits (Shirasaka et al., 1999; Matsumura et al., 2001; Samson
et al., 2007) central administration (icv) of orexin increases
ABP (Samson et al., 1999; Shirasaka et al., 1999; Matsumura
et al., 2001), and SNA (Shirasaka et al., 1999; Matsumura et al.,
2001) in a dose dependent manner, and the increased ABP,
HR and SNA induced by orexin is accompanied by an increase
in plasma catecholamines (Figure 4) (Shirasaka et al., 1999;
Matsumura et al., 2001). Intravenous injection of a ganglionic-
blocking agent, pentolinium, can abolish OX-A induced increases
in ABP and plasma epinephrine concentrations, which suggests
that the pressor response induced by the icv injection of orexin-
A can be attributed primarily to enhanced sympathetic outflow
(Matsumura et al., 2001). Focal injection of OX-A into the RVLM
can also induce a significant increase in ABP andHR in both anes-
thetized (Chen et al., 2000; Shahid et al., 2012) and conscious
(Machado et al., 2002) rats. In anesthetized rats, the increased
ABP is accompanied by increased splanchnic SNA(sSNA) and
ventilation (phrenic nerve activity) that can be attenuated by
blocking OX1R (Shahid et al., 2012). The peak effects follow-
ing OX-A injection into the RVLM were observed at a dose of
50 pmol with ∼42mmHg increase in ABP and 45% increase in
SNA (Shahid et al., 2012).
Other studies also directly and indirectly support orexin’s role
in the regulation of blood pressure and SNA, e.g., intrathecal
injection of OX-A elicits a dose-dependent increase in ABP, HR
(Antunes et al., 2001; Shahid et al., 2011), and sSNA (Shahid et al.,
2011), and the effects can be partially attenuated by either beta-
adrenergic or alpha-adrenergic receptor antagonists (Antunes
et al., 2001) or OX1R antagonist (Shahid et al., 2011) in anes-
thetized rats. Microinjection of OX-A into the medullary raphe
significantly increases ABP, HR, and body temperature in unanes-
thetized rats, (Luong and Carrive, 2012). It is well known that
orexins are excitatory neuropeptides that also promote loco-
motion such as chewing and grooming (Shirasaka et al., 1999;
Takakusaki et al., 2005; Thorpe and Kotz, 2005). To exclude the
possible effects of increased locomotion on the changes in ABP,
FIGURE 2 | Orexin A excites RVLM neurons in vitro. The OX-A induced
depolarization of RVLM neurons (D) was: (1) not significantly affected by
OX1R antagonist SB-334867 (A,D), (2) significantly reduced by an OX2R
antagonist, TCS OX2 29 (B,D), and (3) abolished by simultaneous application
of OX1R and OX2R antagonists (C,D). (Figure used with permission from
Huang et al., 2010). Values are the mean ± S.E.M. with the numbers of
neurons indicated below each bar. ∗Significant difference p < 0.05 (One-Way
ANOVA followed by the Student-Newman-Keuls test).
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FIGURE 3 | Prepro-orexin knockout mice have lower blood pressures
throughout the circadian cycle. The knockout mice have lower blood
pressure in both the light and dark periods of the diurnal cycle relative to
the wild type control mice. Filled circles: KO mice; crosses: WT mice.
(Figure used with permission from Kayaba et al., 2003).
HR and SNA induced by the exogenous orexin in conscious
rats, Shirasaka et al. injected OX-A icv in both anesthetized and
conscious rats and tested them under the same experimental
conditions. They found that OX-A induced a similar significant
increase in ABP, HR and SNA in both anesthetized and conscious
conditions in these rats (Shirasaka et al., 1999), which suggests
that the sympathoexcitatory effects induced by exogenous orexin
in the CSN are not due to the activation of locomotion.
Orexin is involved in the cardio-respiratory responses to acute
stress, e.g., panic and fear (Kuwaki et al., 2008; Furlong et al.,
2009; Iigaya et al., 2012; Johnson et al., 2012; Xiao et al., 2013).
For example, in rats, silencing the hypothalamic pp-OX (Hcrt
gene) with RNAi or antagonizing OX1Rs can block blood pres-
sure and HR responses to acute panic stress (Johnson et al., 2010).
And antagonizing both orexin receptors can: (1) significantly
reduce the “bicuculline” induced stress responses, e.g., hyper-
tension, tachycardia, and renal sympathoexcitation (Iigaya et al.,
2012); (2) decrease the fear induced pressor, tachycardic, and
locomotor responses (Furlong et al., 2009); and (3) decrease the
hypercapnic-induced respiratory chemoreflex without affecting
resting breathing (Li and Nattie, 2010).
In summary, studies in normal animals have shown that the
central orexin system participates in regulation of blood pressure,
HR, and SNA. Activation of OXRs in the CNS, or only the area
of RVLM, by exogenous orexin causes sympathetically mediated
hypertension and tachycardia, which can be attenuated by OXR
antagonists. Orexin is necessary for blood pressure, HR and SNA
responses to certain stresses, e.g., panic and fear.
OREXIN AND HYPERTENSION
The observations that: (a) orexin participates in the regulation of
cardiovascular homeostasis, (b) exogenous orexins can increase
SNA and blood pressure in normal animals, and (c) transgenic
orexin deficient animals have lower resting blood pressure, have
led two independent groups to test the hypothesis that orexin
may participate in the development of neurogenic hypertension
in spontaneously hypertensive rats (SHRs) (Lee et al., 2013; Li
et al., 2013a). The SHR is one of the most studied animal models
of neurogenic hypertension. As in human essential hyperten-
sion, the blood pressure of the SHR rises with age, starting at
about 6 weeks, accompanied by an overactive sympathetic ner-
vous system (Smith and Hutchins, 1979; Zicha and Kunes, 1999;
Simms et al., 2009). We found (Li et al., 2013a,b) in unanes-
thetized freely moving adult SHRs that: (1) there is a strong
trend toward a significant increase in orexin-A mRNA expres-
sion in the RVLM (Figure 5A), a projection site for orexinergic
LHA neurons; (2) blocking both orexin receptors by oral admin-
istration of an antagonist, Almxt: (a) significantly lowers blood
pressure in wakefulness and sleep during both the dark and light
periods of the diurnal cycle, (b) the largest average decrease of
ABP after blocking orexin receptors was in wakefulness during
the dark period (−37mmHg) and the smallest average change
in NREM sleep during the light period (−25mmHg) relative
to the pretreatment baseline, (c) one dose of Almxt produced a
remarkable and long-lasting (∼8 h) reduction of ABP in SHRs
(Figure 6); (3) the anti-hypertensive effect was accompanied by:
(a) a significantly decreased SNA assessed by power spectral anal-
ysis of systolic ABP, and (b) decreased noradrenaline levels in
cerebrospinal fluid and plasma (Figures 5B,C); (4) antagonizing
orexin receptors had no effect on resting blood pressure in nor-
motensive WKY rats (Figure 6B). Our findings are supported
by a recent publication (Lee et al., 2013), which showed that
blocking OX2R centrally by microinjection of an OX2R antago-
nist, TCS-OX2-29, into either the cerebral ventricle (icv) or the
RVLM in anesthetized SHRs significantly decreased blood pres-
sure (Figure 7) (Lee et al., 2013). The significant decrease in ABP
following TCS-OX2-29 was observed at 3, 10, and 30 nmol doses,
and the maximum reduction of ABP was ∼21 or ∼30mmHg at
30 nmol with icv or RVLM injection respectively. It is important
to note that in both studies antagonism of orexin receptor(s) with
either Almxt or TCS-OX2-29 had no significant effect on ABP
in conscious or anesthetized normotensive Wistar- Kyoto (WKY)
control rats.
There are data on cardiovascular effects of the orexin sys-
tem obtained from transgenic animals and hypertensive animal
models that directly and indirectly support an orexin link to
hypertension. Two recent genetic analysis studies showed that
orexin related genes are altered in both SHRs and mice (Schlager
BPH/2J) (Marques et al., 2011a,b; Yamamoto et al., 2013). Like
SHRs, the Schlager high blood pressure mouse (BPH/2J) is
a genetic model of neurogenic hypertension. Using affymetrix
GeneChip mouse gene arrays Marques et al. (2011b) identified
many genes that are differentially expressed in the hypothalamus
of the hypertensive mouse relative to the normotensive BPN/3J
control mice. Among these altered genes, the pp-OX (Hcrt) gene,
which encodes orexin/hypocretin, is significantly increased or up-
regulated in the hypothalamus in the hypertensive mice. BPH/2J
hypertensive mice also exhibit a larger variation in ABP between
the active and inactive periods of the day relative to the normoten-
sive BPN/3J mice, and GeneChip mouse gene arrays showed
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FIGURE 4 | Central application of OX-A increases mean arterial blood
pressure (MAP), heart rate (HR) and renal sympathetic nerve activity
(RSNA) in conscious rats. Intracerebroventricular injection of OX-A
increases MAP, RSNA, HR, and catecholamine release in conscious rats in a
dose dependent manner. Orexin-A (0.3, 3.0 nmol) provoked an increase in
MAP (94.3 ± 0.7 to 101.9 ± 0.7mmHg and 93.1 ± 1.1 to 108.3 ± 0.8mmHg,
respectively) and RSNA (28.0 ± 7.0 and 57.9 ± 12.3%), respectively. (Figure
used with permission from Shirasaka et al., 1999). Left panel: ∗P < 0.05 vs.
vehicle; †P < 0.05 vs. orexin-A (0.3 nmol). Right panel: ∗P < 0.05 vs.
pre-injection values; †P < 0.05 vs. orexin-A (0.3 nmol).
that the pp-OX/Hcrt gene expression is higher during the active
period when ABP is highest than in the inactive period when
ABP is lowest in BPH/2J hypertensive mice, and is higher than
that of in the normotensive control mice during the same period
(Marques et al., 2011a). These genetic and functional studies
in the neurogenic hypertensive animal models suggest that an
up-regulated or overactive central orexin system may play an
important role in developing and maintaining high blood pres-
sure in neurogenic hypertension. It is also interesting to note that
Yamamoto et al (Yamamoto et al., 2013) reported that the OX1R
(Hcrtr1) gene is down-regulated in the adrenal gland in SHR
and stroke-prone SHR (SHRSP) relative to normotensive WKY
rats. This raises an interesting question of the role of peripheral
orexin on cardiovascular function. As mentioned above, orexin
neurons are exclusive located in the lateral hypothalamus and
send projections to many brain locations. However orexins are
found in many peripheral tissues, and the peripheral orexin dis-
tributions and functions have been discussed by recent reviews
(Kukkonen et al., 2002; Spinazzi et al., 2006; Heinonen et al.,
2008; Leonard and Kukkonen, 2013). Orexin receptors have been
detected in various peripheral tissues, e.g., the gastrointestinal
tract, pancreas, kidney, lung, adrenal gland, and adipose tissue
(Kirchgessner and Liu, 1999; Lopez et al., 1999; Johren et al.,
2001; Ouedraogo et al., 2003; Heinonen et al., 2008). In rat, both
www.frontiersin.org February 2014 | Volume 8 | Article 22 | 5
Li and Nattie Orexin participates in regulation of cardio-respiratory function
FIGURE 5 | In the RVLM of SHR, OX-A mRNA expression is increased
as is noradrenaline in CSF and plasma. There is clear trend toward an
increase OX-A mRNA expression in RVLM in SHR relative to normotensive
WKY rats (A). Antagonism OXRs with Almxt significantly decreased the
elevated levels of noradrenaline (NA) in CSF (B), and both NA and
adrenaline (Adr) in plasma in SHRs (B,C). (Figure adapted with permission
from Li et al., 2013a). ∗Significantly difference (P < 0.002, One-Way ANOVA
with Student–Newman–Keuls tests).
OX1R and OX2R mRNA can be detected in adrenal gland (Lopez
et al., 1999; Johren et al., 2001), and the expression of OX2R
mRNA in the adrenal is about eight times higher in male than
that of female rats (Johren et al., 2001, 2004). The adrenal gland
is importantly involved in stress-related cardiovascular function
via the hypothalamic-pituitary-adrenal axis, and the significance
of a down-regulated Hcrt1R gene in adrenal gland of SHRs needs
to be further investigated.
Psychological stresses, e.g., anxiety, prolonged anger, men-
tal stress, have long been considered as a contributing factor
in developing hypertension (Zimmerman and Frohlich, 1990;
Boone, 1991; Markovitz et al., 1993), and as discussed above
orexin is involved in cardiovascular and respiratory responses to
the acute stresses, e.g., panic, fear, drug or foot-shock induced,
in animal models. Xiao et al. recently investigated possible role
of orexin on developing stress related hypertension in adult
Sprague-Dawley (SD) rats (Xiao et al., 2013). A stress induced-
hypertensive rat (SIHR) was generated by intermittent electric
foot-shocks (75–150V, 0.5ms duration) every 2–30 s and a buzzer
noises (88–98 dB) for 2 h twice daily for 14 consecutive days.
Adult normotensive SD rats develop hypertension after day 6
under these conditions. Using tail-cuff method the authors found
the systolic blood pressure at 2 h after stress rose from 110mmHg
at baseline to 142mmHg at day 14 in these SIHRs, and the num-
ber of OX-A immunoreactive (OXA-ir) neurons in the LHA and
the protein level of OX1R in RVLMwere significantly greater than
that of the control rats. Microinjection of a selective OX1R antag-
onist (SB-408124), or a selective OX2R antagonist (TCS OX2 29)
into RVLM can partially block the OX-A induced increased SBP
and HR in SIHR (Xiao et al., 2013). It is interesting to note that,
similar to the neurogenic hypertensive model SHRs, SIHRs also
developed an overactive central orexin system. It would be inter-
esting to see if blocking both OXRs by Almxt or a combination of
OX1R andOX2R antagonists can decrease blood pressure between
days 6 and 14 in these SIHRs and prevent the development of
hypertension.
The potential peripheral effects of orexins on blood pressure
and SNA have been investigated (Chen et al., 2000; Matsumura
et al., 2001). Intravenous injection of OX-A or OX-B at a dose
as high as 11 nmol/kg had no significant effect on ABP, HR or
SNA in anesthetized rats and conscious rabbits, which suggests
that the orexin effects on ABP, HR, and SNA are mediated pri-
marily through the CNS (Chen et al., 2000; Matsumura et al.,
2001). At the present time there is little evidence to support a role
for peripheral orexins in the regulation of cardiovascular function
(Heinonen et al., 2008; Kukkonen, 2013).
In summary: (1) Transgenic orexin deficient animals have a
lower resting blood pressure. (2) BlockingOXRs significantly low-
ers blood pressure and SNA in adult SHRs. (3) PP-OX mRNA
and gene expression are upregulated in the CNS in hyperten-
sive rats and mice. Based on these findings we suggest that an
overactive orexin system in the CNSmay participate in the patho-
genesis and maintenance of high blood pressure in certain forms
of hypertension. Further, modulation of the orexin system could
be a potential target in treating some forms of hypertension.
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FIGURE 6 | In SHR, antagonism of OXRs with a systemic OXR
antagonist, Almxt, decreases arterial pressure. One does of orally
administered amlxt significantly decreased arterial pressure in SHR for ∼8h
(A), and Almxt had no effect on arterial pressure in normotensive WKY rats
(B). The largest decrease of BP after Almxt is in wakefulness during the dark
period (−37mmHg) and smallest change is in NREM sleep during the light
period (−25mmHg) relative to the pretreatment baseline (C). ∗P < 0.02
(Figure adapted with permission from Li et al., 2013a).
SUMMARY OF THE ROLE OF OREXIN IN CARDIOVASCULAR FUNCTION
In normal animals, activation of OXRs by orexin in the CNS or
in areas critically involved in SNA regulation, e.g., the RVLM
and spinal cord, induces sympathetically mediated hypertension
and tachycardia, which can be attenuated by OXR antagonists.
Transgenic orexin deficient animals have a lower resting blood
pressure. Spontaneously hypertensive rats and mice may have
an overactive orexin system as (1) blocking OXRs produces
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FIGURE 7 | In anesthetized SHR, antagonism of OX2R in RVLM
decreases arterial pressure. Microinjection of an OX2R antagonist
(TCS-OX2-29) into the RVLM significantly decreased mean AP and HR in
anesthetized SHR (A,C), and the maximum change of mean AP and HR
being 30mmHg and 20 bpm respectively (C, gray hatched bars). It is
important to note that blocking OX2R in RVLM in normotensive WKY rats
had no effect on ABP and HR (B,C, white hatched bars). Control vehicle
(ACSF) injection had no effect on AP and HR in SHR and WKY rats
(A,B,C). (Figure adapted with permission from Lee et al., 2013).
∗,#Significant difference (p < 0.05).
significant anti-hypertensive effects in SHRs, (2) the expression
of OX-A mRNA in increased in RVLM in SHRs and (3) the pp-
OX/Hcrt gene is upregulated in hypothalamus in hypertensive
BPH/2J mice. Orexin is important in the regulation of SNA and
blood pressure and an overactive orexin system may be patholog-
ically linked to the development of neurogenic hypertension.
OREXIN AND RESPIRATION: THE CENTRAL CHEMOREFLEX
AND BLOOD PRESSURE REGULATION
OREXIN, RESPIRATION, AND THE HYPERCAPNIC CHEMOREFLEX
Anatomically the orexin system is well positioned to be involved
in the regulation of respiration and central chemoreception.
Orexin neurons innervate many brainstem respiratory nuclei
including the RTN, medullary raphe, LC, NTS, and pre-Bötzinger
complex (Peyron et al., 1998; Date et al., 1999; Kukkonen et al.,
2002; Young et al., 2005; Puskas et al., 2010; Lazarenko et al.,
2011; Tupone et al., 2011; Nixon et al., 2012). Retrograde trac-
ing studies showed that LHA OX-A positive neurons project to
the diaphragm (Young et al., 2005; Badami et al., 2010) and
raphe pallidus (Tupone et al., 2011). In Phox2b-eGFP transgenic
mice, Lazarenko et al. further showed that the orexin-containing
axonal varicosities are closely positioned relative to RTN Phox2b
expressing neurons (Lazarenko et al., 2011). The expression of
OX1R and/or OX2R mRNA is also found abundantly in many
respiratory nuclei in the brainstem with a pattern matching that
of OX-containing axon terminals (Marcus et al., 2001; Kukkonen
et al., 2002).
At the cellular level, using in vitro patch-clamp recordings in
visualized orexin neurons in brain slices, Williams et al., showed
that the orexin neurons are intrinsically CO2 (Figure 8A) and pH
(Figure 8B) sensitive (Williams et al., 2007). The orexin neurons
in LHA increase their firing rate during acidification and decrease
their firing rate during alkalization (Figure 8), while non-orexin
neurons are not responsive to such changes (Figure 8C) (Williams
et al., 2007). These effects are mediated, at least in part, by the
TASK-like tandem-pore K+ channels (Williams et al., 2007), and
possibly by other acid-sensing channels, e.g., ASICs (Song et al.,
2012).
In addition to their intrinsic CO2/pH sensitivity, orexin neu-
rons also modulate the activity of brainstem chemosensitive neu-
rons such as those in medullary raphe nuclei and RTN (Dias et al.,
2010; Lazarenko et al., 2011; Tupone et al., 2011; Nattie and Li,
2012). Electrophysiological studies in slices from neonatal (P6-
P10) Phox2b-eGFP transgenic mice showed that orexin A excites
the acid sensitive eGFP/Phox2b-expressing RTN neurons in a
dose dependent manner (ED50 ∼250 nM, Figure 9), and these
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FIGURE 8 | Orexin neurons in LHA are intrinsically CO2 and pH
sensitive.In vitro current-clamp whole-cell recordings of GFP tagged orexin
neurons of the Phox2b-eGFP mice show: (A) orexin (OX) neurons are
intrinsically CO2 chemosensitive, Firing rate was 0.8 ± 0.3Hz in 5% CO2
and increased to 3.7 ± 0.4Hz in 10% CO2 (n = 5; P < 0.01); (B) orexin
neurons are intrinsically pH chemosensitive. Firing rate was 4 ± 0.6Hz at
pH 6.9 and decreased to 0.5 ± 0.2Hz at pH 7.4 (n = 15; P < 0.001); and (C)
non-orexin neurons in the same region are not pH chemosensitive. (Figure
used with permission from Williams et al., 2007).
neurons increased activity upon bath acidification, decreased fir-
ing with alkalization, and exhibited an ∼5Hz dynamic range
of response between pH 7.0 and 7.5 (Figures 9A,B) (Lazarenko
et al., 2011). Functional studies have shown that the orexin sys-
tem participates in the regulation of respiration and the CO2
central chemoreflex (Dutschmann et al., 2007; Nakamura et al.,
2007; Williams et al., 2007; Dias et al., 2009, 2010; Li and Nattie,
2010; Lazarenko et al., 2011). Microinjection of orexin into the
RVLM at the level of the pre-Bötzinger complex causes a signif-
icant increase in amplitude of integrated phrenic nerve activity
(an index of tidal volume) in anesthetized and vagotomized rats
(Young et al., 2005; Shahid et al., 2012). Injection of OX-B into
the Kölliker–Fuse nucleus significantly increases breathing fre-
quency in P21–42 day rats using the intra-arterially perfused
working heart-brainstem preparation (Dutschmann et al., 2007).
In the decerebrate cat, OX-A application into the hypoglos-
sal motor nucleus increases genioglossus muscle activity (Peever
et al., 2003). The pp-OX knockout mouse with a complete lack
of orexin has normal resting breathing but a significantly attenu-
ated respiratory chemoreflex in wakefulness compare to the wide
type control mice and supplementation of orexins can partially
restore the reflex (Deng et al., 2007; Nakamura et al., 2007).
Unilateral administration of an OX1R antagonist (SB334867) in
the RTN significantly reduced the respiratory response to hyper-
capnia (7%CO2) with a substantial effect in wakefulness (−30%;
Figure 10A) and a much smaller effect in sleep (−9%) (Dias
et al., 2009). In the medullary raphe, inhibition of the OX1R
produced a significant reduction of the CO2 chemoreflex in wake-
fulness (−16%; Figure 10B) but not in sleep (Dias et al., 2010).
Antagonism both OX1R and OX2R by orally administrating a
dual OXR antagonist, Almxt, significantly decreased the hyper-
capnic chemoreflex only in wakefulness during the dark period
of diurnal cycle (−31%); the CO2 chemoreflex was not signifi-
cantly changed in sleep in the dark period and wakefulness and
sleep in the light period of the diurnal cycles (Figure 11) (Li and
Nattie, 2010). Antagonism of orexin receptors had no effect on
resting breathing (Dias et al., 2009, 2010; Li and Nattie, 2010).
FIGURE 9 | Orexin A excites acid sensitive eGFP/Phox2b-expressing
RTN neurons in vitro. Electrophysiological recordings in slices from
neonatal (P6-P10) Phox2b-eGFP mice show that OX-A excited
eGFP-expressing RTN neurons in a dose-related manner (A). The
neuron increased activity upon bath acidification, decreased firing with
alkalization with an ∼5Hz dynamic range of response between pH 7.0
and 7.5 (A,B). (Figure used with permission from Lazarenko et al.,
2011).
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FIGURE 10 | Focal application of an OX1R antagonist in the RTN and
the medullary raphe magnus decreases the CO2 chemoreflex. Inhibition
of OX1R in the region of RTN (unilateral, A) or raphe magnus (B) by an
OX1R antagonist (SB334867) significantly decreased the CO2 chemoreflex
by 30 or 16% respectively in wakefulness. (Figure adapted with permission
from Dias et al., 2009 and Dias et al., 2010).
These in vitro and in vivo experiments demonstrate that the
orexin system is significantly involved in the control of breathing,
particularly in the central CO2 chemoreflex.
In summary: (1) Orexin neurons are intrinsically chemosen-
sitive and send projections to other central chemoreceptor sites,
e.g., the RTN and medullary raphe. (2) Orexin may regulate
breathing and central chemoreception directly and/or indirectly
by recruiting other brainstem chemoreceptor sites, e.g., the
RTN and medullary raphe. (3) Orexin modulation of the CO2
chemoreflex may be vigilance state dependent with the strongest
effect being during wakefulness in the dark period. (4) Orexin
may be a link between breathing and sleep-wake status.
RESPIRATION AND CENTRAL CHEMORECEPTION IN BLOOD PRESSURE
REGULATION
Respiration, sympathetic activity, and blood pressure
Anatomically, many cardiovascular and respiratory related nuclei
are closely intertwined within similar regions of the brain, or
are even synaptically connected. Many of these nuclei are part of
the respiratory-sympathetic network that is critical to the regula-
tion of respiratory and sympathetic activity and blood pressure
(Rosin et al., 2006; Zoccal et al., 2009a; Geerling et al., 2010;
Guyenet et al., 2010). For example, in the brainstem, both the
FIGURE 11 | Systemic antagonism of OXRs decreases the CO2
chemoreflex. Antagonism of both OX1R and OX2R by orally administrating
a dual OXR antagonist, Almxt, significantly decreased the hypercapnic
chemoreflex only in wakefulness during the dark period of diurnal cycle
(−26%). In the dark period, there was a significant difference between the
ventilation breathing 7% CO2 in control compared to Almxt treatment in
the awake state (∗P < 0.05). (Figure used with permission from Li and
Nattie, 2010).
RVLM and the caudal ventrolateral medulla (CVLM), sites crit-
ically involved in the regulation of sympathetic tone, overlap
with the ventral respiratory column including Bötzinger and pre-
Bötzinger neurons. The neurons in the RTN, a putative central
chemoreceptor site, innervate the entire ventrolateral medulla
including the ventral respiratory column (VRC) and areas criti-
cally involved in the ABP and SNA regulation, e.g., the RVLM and
CVLM (Rosin et al., 2006). The hypothalamic PVN, an important
site for autonomic and endocrine homeostasis, is anatomically
connected with many putative central chemoreceptors sites, e.g.,
the RTN, LC, NTS and medullary raphe (Geerling et al., 2010).
The sympathetic preganglionic neurons (SPGNs) in the spinal
cord receive prominent innervation from spinal interneurons, the
RVLM, themidlinemedulla oblongata includingmedullary raphe
serotonergic neurons, the pontine A5 noradrenergic cell group,
the dorsolateral pons, the hypothalamic PVN, and the orexinergic
neurons in the LHA (Jansen et al., 1995). The complex anatom-
ical connections between the respiratory sites, central chemore-
ceptor sites and cardiovascular regulation sites suggest that the
central respiratory chemoreflex is positioned to participate in
the regulation or modulation of sympathetic activity and blood
pressure.
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Central chemoreception, SNA and blood pressure
Activation of central chemoreceptors by CO2/H+ increases ABP
and SNA in both humans and experimental animals (Hanna
et al., 1981; Lioy and Trzebski, 1984; Somers et al., 1989; Nattie
et al., 1992, 1993; Oikawa et al., 2005; Guyenet et al., 2010).
In humans, hyperoxic hypercapnia (7%CO2/93%O2) induced
greater increases in ventilation (V˙E), blood pressure and SNA
than did hypoxia (10%O2/93%N2) (Somers et al., 1989). In
conscious rats (Figure 12), Oikawa et al. (2005) showed that
hypercapnia induced significant increases in mean ABP, RSNA,
and the respiratory rate (Figure 12B) in intact animals and in
animals with varied peripheral chemoreceptor input, e.g., carotid
body destroyed (CBD), aortic nerve denervated (AD), carotid
body destroyed plus aortic denervated (CBAD), and sinoaor-
tic denervated (SAD) (Figure 12C). There were also no sig-
nificant differences in the magnitudes of increase in ABP and
RSNA during hypercapnia between the intact and the chemo-
denervated groups (Figure 12). The fact that the increased ABP
and rSNA response to hypercapnia was not affected by bilateral
carotid chemo-denervation, aortic denervation, or sinoaortic-
denervation suggests that the peripheral chemoreceptors do not
play a major role in the cardiovascular response to hypercapnia
in normal conscious rats (Oikawa et al., 2005). Blockade of glu-
tamate receptors in the RTN or lesion of the rostral part of the
RVLM decreased respiratory (phrenic nerve activity, PNA) and
SNA responses to hypercapnic stimulation in decerebrate, para-
lyzed, vagotomized, and servo-ventilated cats (Nattie et al., 1992,
1993).
In summary: (1) Many putative central chemoreceptors sites,
e.g., the RTN, NTS and medullary raphe, are involved in
the regulation of SNA and blood pressure. (2) Activation of
central chemoreceptors by hypercapnia significantly increases
blood pressure, SNA and respiration with and without periph-
eral chemoreceptors. These studies suggest that the hypercapnic
induced increase in ABP is due to sympatho-excitation via activa-
tion of the central chemoreceptors. The central chemoreceptors
directly or indirectly regulate sympathetic vasomotor tone and
blood pressure, and can activate the sympathetic outflow in a
tonic manner independent of the effects on the central respiratory
pattern generator (Moreira et al., 2006; Guyenet et al., 2010).
SUMMARY OF OREXIN AND RESPIRATION: THE CENTRAL
CHEMOREFLEX AND BLOOD PRESSURE REGULATION
Orexin neurons are intrinsically chemosensitive and their pro-
jections and receptors are found densely in all the major
respiratory neuronal groups and central chemoreceptor sites.
Activation of central chemoreceptors with and without activation
of peripheral chemoreceptors leads to significant sympathoexcita-
tion and hypertension in both human and experimental animals.
Respiration and the central chemoreflex are involved in regulation
of SNA and blood pressure.
OREXIN, CHEMOREFLEX, AND HYPERTENSION
Overactive vasoconstrictor sympathetic tone, an enhanced
peripheral chemoreflex, and an impaired baroreflex have been
found in a significant portion of patients with primary hyper-
tensive as well as in SHRs (Izdebska et al., 1982; Simms et al.,
2009; Tan et al., 2010). In susceptible individuals, stress or
altered physiology initiates increases in sympathetic activity to
cardiovascular resistance vessels accompanied by increases in
blood pressure. Over time, vascular smooth muscle in resis-
tance vessels hypertrophies resulting in persistent hypertension.
The SHR is one of the most used animal models of neuro-
genic hypertension and SHRs develop hypertension at about 6
weeks of life. Using the working heart–brainstem preparation,
Simms et al., showed that the respiratory related sympathetic
tone is significantly higher in SHRs relative to normotensive
WKY rats starting from postnatal day 9–16, well before the
onset of hypertension (Simms et al., 2009). They suggest that
this augmented respiratory-sympathetic coupling in SHR and
its effect on the vascular tone in early life is a causal factor in
developing hypertension (Simms et al., 2009, 2010). However,
the mechanisms leading to such changes remain unclear at
present time.
PERIPHERAL CHEMOREFLEX AND HYPERTENSION
A link between neurogenic hypertension and an enhanced carotid
body chemoreflex has been more extensively studied in patients
and in animal models of sleep apnea (Fletcher et al., 1992; Lesske
et al., 1997; Fletcher, 2001; Prabhakar et al., 2001, 2005, 2012;
Schultz et al., 2007; Simms et al., 2010; Zoccal and Machado,
2011; Costa-Silva et al., 2012; Moraes et al., 2012a,b; Paton et al.,
2013). The peripheral chemoreceptor reflex response has been
shown to be significantly enhanced in patients with primary
hypertension (Trzebski et al., 1982; Tafil-Klawe et al., 1985a,b;
Somers et al., 1988a,b; Sinski et al., 2012) and in animal models
of systemic hypertension, e.g., SHRs (Fukuda et al., 1987; Simms
et al., 2009; Tan et al., 2010). Rats exposed to chronic intermittent
hypoxia (CIH) develop hypertension and persistent sympathetic
activation, and elimination of the carotid bodies prevents such
CIH-induced hypertension (Fletcher et al., 1992; Lesske et al.,
1997). Enhanced carotid body activity has been suggested to
result in alterations in respiratory–sympathetic coupling (Simms
et al., 2009; Zoccal et al., 2009b) and increased muscle vasocon-
strictor activity, which may contribute to the development of
hypertension (Trzebski et al., 1982; Somers et al., 1988a). The
hyperactive carotid chemoreceptors are accompanied by overex-
pression of ASIC/TASK (acid-sensing ion channel/2-pore domain
acid-sensing K+ channel) channels in young pre-hypertensive
SHRs (Tan et al., 2010). Abdala et al., further showed that bilateral
denervation of the carotid sinus nerves (CSD) in SHRs can signif-
icantly lower the resting blood pressure (∼25mmHg), respiratory
frequency (transiently) and the low frequency component of the
frequency analysis of systolic blood pressure, an index of sympa-
thetic vasomotor tone (Figure 13), and they suggested that the
inputs of carotid sinus nerve from the carotid body are partially
responsible for increased SNA and blood pressure in SHR (Abdala
et al., 2012).
In summary: an enhanced peripheral chemoreceptor reflex
is found in both human hypertension and SHRs, and bilat-
eral denervation of the carotid sinus nerves can partially lower
blood pressure in SHRs. It is suggested that this enhanced carotid
body activity may contribute to the alterations in respiratory–
sympathetic coupling in SHRs.
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FIGURE 12 | In conscious rats, hypercapnia increases arterial blood
pressure (ABP) and renal sympathetic nerve activity (RSNA).
Hypercapnia increased mean ABP [from 105 to 117mm Hg; (A)], RSNA
[from 100 to 115%, (A,B)], and the respiratory rate [from 63 to 151
breaths/min; (A)], but decreased HR [from 374 to 302 beats/min; (A,B)].
Hypercapnia significantly increased mean ABP and RSNA in intact (A),
carotid body destroyed (CBD), aortic nerve denervated (AD), carotid body
destroyed and aortic denervated (CBAD), and sinoaortic denervated (SAD)
rats (C). There were also no significant differences in the magnitudes of
increase in ABP and RSNA during hypercapnia between the intact and the
three chemo-denervated groups. (Figure adapted with permission from
Oikawa et al., 2005).
Frontiers in Neuroscience | Neuropharmacology February 2014 | Volume 8 | Article 22 | 12
Li and Nattie Orexin participates in regulation of cardio-respiratory function
FIGURE 13 | In SHR, carotid body denervation decreases blood
pressure, respiratory frequency and sympathetic nerve activity.
Bilateral denervation of carotid sinus nerves (CSD) significantly decrease
resting blood pressure, respiratory frequency (RR; transiently) and a SNA
index (SBP LF) in SHRs. Systolic pressure decreased over 5–10 days to
reach a plateau of −17 ± 3mmHg (n = 10, P < 0.05). Mean arterial and
diastolic pressures fell by −15 ± 2 (P < 0.05) and −17 ± 2
(P < 0.05)mmHg, respectively. Lowered arterial pressure was maintained
with no sign of recovery for at least 3 weeks. SBP LF: Systolic blood
pressure, low frequency band. (Figure used with permission from Abdala
et al., 2012). #Significant difference (P < 0.05).
CENTRAL CO2 CHEMORECEPTION, HYPERTENSION
As discussed above it is well established that activation of cen-
tral chemoreceptors by CO2 increases breathing, SNA and blood
pressure in humans and in anesthetized and conscious animals
(Hanna et al., 1981; Lioy and Trzebski, 1984; Somers et al., 1989;
Nattie et al., 1992, 1993; Oikawa et al., 2005; Guyenet et al.,
2010). In asphyxia, the hypercapnic component is of greater
importance than the hypoxic component in causing sympathet-
ically induced increases in ABP and vascular resistance (Morgan
et al., 1995; Cooper et al., 2004). However, the links between neu-
rogenic hypertension and the hypercapnic central chemoreflex
are not well understood. In human subjects, the hypoxic com-
ponent of asphyxia reduces the baroreceptor–vascular resistance
reflex sensitivity, while the hypercapnic component is respon-
sible for increasing blood pressure (Cooper et al., 2004, 2005).
Thus, the effects of both peripheral and central chemorecep-
tors may contribute to promoting hypertension in patients with
obstructive sleep apnea who undergo repeated bouts of asphyxia
nightly (Cooper et al., 2005). Combined hypoxia and hyper-
capnia evoke longer-lasting sympathetic activation in humans
than does either hypoxia or hypercapnia alone (Morgan et al.,
1995). In patients with heart failure, the central chemoreflex
response to hypercapnia is markedly and selectively enhanced
(Kara et al., 2003; Yamada et al., 2004), and the enhanced hyper-
capnic chemosensitivity is correlated significantly with plasma
norepinephrine levels suggesting sympathoexcitation (Kara et al.,
2003). Administration of 100% oxygen does not lower sympa-
thetic activity in patients with heart failure, providing further
evidence against any peripheral chemoreflex potentiation (Kara
et al., 2003). In anesthetized SHRs with carotid sinus denerva-
tion, systemic hypercapnia increased and hypocapnia decreased
the magnitude of both phrenic and sympathetic discharges, and
the increased sympathetic discharge during hypercapnia was
accompanied by a significant increase in ABP (Czyzyk-Krzeska
and Trzebski, 1990).We have recently reported that SHRs have
a significantly augmented central hypercapnic chemoreflex rel-
ative to the normotensive WKY control rats (Li and Nattie,
Neuroscience, 2012). In SHRs, the ventilatory response to nor-
moxic hypercapnia (7% CO2/21%O2), or hyperoxic hypercap-
nia (7%CO2/93%O2) when peripheral chemoreceptors are sup-
pressed, is significantly higher in both wakefulness and sleep
than that of the normotensive WKY control rats (Li and Nattie,
Neuroscience, 2012). It is interesting to note that both periph-
eral and central chemoreflexes have powerful effects on sym-
pathetic activity (see above), and in SHRs both the peripheral
and central chemoreflex are overactive. Asphyxia, a recurring
condition in sleep disorders, includes two important compo-
nents, hypoxia and hypercapnia, which are primarily detected
by peripheral and central chemoreceptors, respectively, in nor-
mal conditions. Sleep disorders are present in ∼ 40% of obese
individuals and both sleep disorders and obesity are closely asso-
ciated with hypertension (Chau et al., 2012). Many studies have
focused on the hypoxic effects of sleep disorders and hypertension
with little attention to the role of the central CO2 chemoreflex
in sleep disorders and their link to the development of hyper-
tension. It is also interesting to note that while denervation of
the peripheral chemoreceptor in SHRs significantly lower ABP
(up to ∼25mmHg), ABP remains significantly above the nor-
mal even at 21 days post CSD (Abdala et al., 2012) suggesting
other possiblemechanisms are involved, e.g., an overactive central
chemoreflex.
In summary: in SHRs, the respiratory chemoreflex to hyper-
capnia is exaggerated with and without peripheral carotid
chemoreceptor inputs.
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OREXIN, CENTRAL CHEMORECEPTORS, AND HYPERTENSION
That activation of orexin receptors evokes increases in breath-
ing, SNA, and ABP, and that SHRs have augmented central
and peripheral chemoreflexes suggest that orexin is a key fac-
tor that links the cardiovascular and respiratory systems, and
that alterations of the orexin system may contribute to some
cardio-respiratory diseases. The following observations support
this proposed link: (1) The orexin knockout mouse has a
decreased respiratory hypercapnic chemoreflex as well as a lower
resting ABP (Kayaba et al., 2003; Nakamura et al., 2007). (2)
Orexin injections into the CNS increase ABP, HR, SNA, and
breathing in both conscious and anesthetized normotensive ani-
mals (Shirasaka et al., 1999; Machado et al., 2002; Huang et al.,
2010; Shahid et al., 2011, 2012). (3) The SHRs have: (a) an aug-
mented respiratory–sympathetic coupling in reduced prepara-
tions (Simms et al., 2009), (b) a hyperactive peripheral chemore-
flex (Zoccal et al., 2008; Simms et al., 2009), and (c) a hyperactive
central CO2 chemoreflex (Li and Nattie, Neuroscience, 2012). (4)
Blockade of both OXRs can significantly lower ABP, HR, SNA
and the hyperactive central CO2 chemoreflex in conscious SHRs
(Li et al., 2013a). Based on these data, we pose the following
questions: (1) What is the role of overactive central chemorecep-
tors in developing hypertension? (2) What is the role of orexin
in this augmented CO2 chemoreflex and hypertension? (3) Can
antagonism of OXRs be a target to treat such an augmented CO2
response and the associated hypertension in SHR? At present, we
have found that antagonism of both OXRs using an orally admin-
istered dual orexin receptor antagonist, Almxt: (1) significantly
reduced the exaggerated CO2 chemoreflex in SHR to the same
level as measured in the control normotensive WKY rats (Li and
Nattie, Neuroscience, 2012), and (2) significantly decreased ABP
in both resting and hypercapnic condition (Li et al., 2013a) (Li
and Nattie, Neuroscience, 2012). We hypothesize that the source
of the enhanced SNA and respiratory-sympathetic coupling may
involve neurons in the central chemoreceptor sites, and the over-
active central orexin systemmay play an important role in such an
alteration. There is no evidence that orexin projections and orexin
receptors are located in the peripheral chemoreceptors, e.g., the
carotid body, at the present time and the role of peripheral orex-
ins in regulation of cardio-respiratory functions remain unclear
(Johren et al., 2001; Nakabayashi et al., 2003; Heinonen et al.,
2008).
In summary: transgenic orexin deficient mice and rats have
lower resting blood pressure, and a significantly decreased hyper-
capnic response (pp-OX KO) while SHRs have severe hyperten-
sion, a hyperactive central hypercapnic reflex, and possibly an
overactive orexin system. Blocking both orexin receptors in SHR
can normalize the exaggerated hypercapnic chemoreflex and sig-
nificantly lower blood pressure, which suggests the overactive
central chemoreceptors may be an important link in neurogenic
hypertension with orexin as mediator in SHRs.
SUMMARY OF OREXIN, CHEMOREFLEX, AND HYPERTENSION
Orexin knockout mice have both a severely attenuated hypercap-
nic chemoreflex and lower resting blood pressure, while SHRs
have severely increased blood pressure and enhanced peripheral
and central chemoreflexes with a possibly upregulated central
orexin system. Antagonism of both orexin receptors can signifi-
cantly lower SNA and blood pressure and normalize that central
hypercapnic chemoreflex in SHRs. We suggest that overactive
central chemoreceptors may be an important link to the devel-
opment and maintenance of high blood pressure in SHRs with
orexin as a key mediator.
CONCLUSION
Activation of central CO2 chemoreceptors is associated with
sympatho-excitation, hypertension and tachycardia. In SHRs, the
overactive central and peripheral chemoreflexmay play an impor-
tant role in the development of neurogenic hypertension. Orexin
links the respiratory and sympathetic nervous systems and an
overactive orexin system may be the cause of hyperactive central
CO2 chemoreflex in SHRs and thus the associated hypertension.
Antagonism of OXRs can normalize the overactive CO2 central
chemoreflex and significantly lower ABP and SNA in SHRs. Based
on the data obtained from SHRs we hypothesize that modulation
of the orexin system could be a potential target in treating some
forms of hypertension.
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